[Therapeutic effect of S1P receptor modifying drugs for autoimmune diseases].
Chiba
Kenji
K
Kataoka
Hirotoshi
H
D000818:Animals; D001327:Autoimmune Diseases / Q000188:drug therapy*; D017322:Clinical Trials, Phase II as Topic; D004195:Disease Models, Animal; D015195:Drug Design; D000068876:Fingolimod Hydrochloride; D006801:Humans; D007166:Immunosuppressive Agents / Q000494:pharmacology* / Q000627:therapeutic use*; D009103:Multiple Sclerosis / Q000188:drug therapy; D011409:Propylene Glycols / Q000008:administration & dosage / Q000494:pharmacology* / Q000627:therapeutic use*; D049349:Receptors, Lysosphingolipid / Q000819:agonists* / Q000502:physiology*; D013110:Sphingosine / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000494:pharmacology / Q000627:therapeutic use
D007166:Immunosuppressive Agents; D011409:Propylene Glycols; D049349:Receptors, Lysosphingolipid; D000068876:Fingolimod Hydrochloride; D013110:Sphingosine